Pfizer Inc. $PFE Position Boosted by PFG Investments LLC

PFG Investments LLC raised its holdings in shares of Pfizer Inc. (NYSE:PFE) by 5.9% during the 2nd quarter, HoldingsChannel reports. The fund owned 250,474 shares of the biopharmaceutical company’s stock after purchasing an additional 14,016 shares during the period. PFG Investments LLC’s holdings in Pfizer were worth $6,071,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. GKV Capital Management Co. Inc. purchased a new position in Pfizer during the first quarter valued at approximately $27,000. Bayforest Capital Ltd purchased a new position in shares of Pfizer during the 1st quarter valued at $28,000. North Capital Inc. purchased a new position in shares of Pfizer during the 1st quarter valued at $28,000. WPG Advisers LLC purchased a new position in shares of Pfizer during the 1st quarter valued at $35,000. Finally, Horizon Financial Services LLC purchased a new position in shares of Pfizer during the 1st quarter valued at $35,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on PFE shares. Morgan Stanley boosted their target price on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. Citigroup boosted their price target on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday. Finally, Bank of America boosted their price target on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $28.12.

Pfizer Price Performance

NYSE PFE opened at $25.46 on Wednesday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The company has a fifty day simple moving average of $24.55 and a 200 day simple moving average of $24.11. The company has a market cap of $144.75 billion, a P/E ratio of 13.54, a P/E/G ratio of 0.77 and a beta of 0.55. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. During the same period in the prior year, the company earned $0.60 earnings per share. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.